Sexual Dysfunction and Quality of Life in Patients with Hidradenitis Suppurativa and Their Partners.
erectile dysfunction
hidradenitis suppurativa
quality of life
sexual dysfunction
sexual partners
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
26 12 2022
26 12 2022
Historique:
received:
17
11
2022
revised:
21
12
2022
accepted:
22
12
2022
entrez:
8
1
2023
pubmed:
9
1
2023
medline:
11
1
2023
Statut:
epublish
Résumé
Hidradenitis suppurativa (HS) is a chronic skin disease that profoundly affects patients' quality of life (QoL) and sexuality. Few data are available on the impact of HS on patients' partners. We aimed to explore the QoL and sexual function of patients' partners and the factors associated with their impairment and to compare the QoL and sexual function of single patients and those in a stable relationship. We conducted a cross-sectional study at Hospital Universitario Virgen de las Nieves (Granada, Spain) and at the Wroclaw Medical University (Wroclaw, Poland). Patients over the age of 16 years attending their scheduled follow-up and their partners, if any, were included. The Dermatology Life Quality Index (DLQI) and the Family Dermatology Life Quality Index (FDLQI) were used to estimate the QoL of patients and partners, respectively. The FSFI-6 was used to determine sexual dysfunction in women and the IIEF-5 for erectile dysfunction in men. Thirty-four single patients and twenty-eight patients in a stable relationship and their partners were included. Patients had a very large impact (DLQI 12.5 ± 7.5) and their partners a moderate impact (FDLQI 10.3 ± 7.1) in their QoL due to HS. Women with HS had a high prevalence of sexual dysfunction (13/32, 40.6%) and men of erectile dysfunction (19/30, 63.3%). Male partners also had a high prevalence of erectile dysfunction (10/17, 58.8%), while only one female partner had sexual dysfunction (1/11, 9.1%). Factors related to disease severity, intensity of symptoms and body mass index were associated with poorer QoL in partners and time of disease evolution with greater erectile dysfunction in male partners. In conclusion, HS not only profoundly affects the QoL and sexuality of patients but also of their partners. Several risk factors have been identified, which should be taken into account in the holistic approach of the disease.
Identifiants
pubmed: 36612709
pii: ijerph20010389
doi: 10.3390/ijerph20010389
pmc: PMC9819626
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Environ Res Public Health. 2020 Aug 18;17(16):
pubmed: 32824800
J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1151-5
pubmed: 22882670
Int J Environ Res Public Health. 2020 Nov 27;17(23):
pubmed: 33260862
Int J Womens Dermatol. 2018 Feb 01;4(2):74-79
pubmed: 30023423
Dermatology. 2020;236(1):59-65
pubmed: 31466061
Am J Clin Dermatol. 2013 Dec;14(6):489-95
pubmed: 23839260
Wound Repair Regen. 2015 Sep;23(5):778-80
pubmed: 26074170
J Clin Med. 2022 Jul 26;11(15):
pubmed: 35893421
Skin Res Technol. 2019 Nov;25(6):830-834
pubmed: 31140660
J Clin Med. 2022 Apr 21;11(9):
pubmed: 35566438
JAMA Dermatol. 2018 Apr 1;154(4):447-451
pubmed: 29466546
Dermatology. 2021;237(5):727-732
pubmed: 33477150
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
Br J Dermatol. 2020 Dec;183(6):e171-e177
pubmed: 29744872
Biomedicines. 2022 Nov 09;10(11):
pubmed: 36359387
Br J Dermatol. 2017 Nov;177(5):1401-1409
pubmed: 28636793
J Am Acad Dermatol. 2014 Aug;71(2):302-7
pubmed: 24836080
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1822-1827
pubmed: 32003871
J Clin Med. 2019 Apr 18;8(4):
pubmed: 31003427
J Am Acad Dermatol. 2017 Jan;76(1):49-53
pubmed: 27793450
Acta Derm Venereol. 2017 Apr 6;97(4):478-482
pubmed: 27819713
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1221-4
pubmed: 24981284
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Acta Derm Venereol. 2010 May;90(3):264-8
pubmed: 20526543
Dermatology. 2016;232(6):687-691
pubmed: 28052274
Br J Dermatol. 2007 Mar;156(3):528-38
pubmed: 17300244
J Sex Med. 2010 Mar;7(3):1139-46
pubmed: 19968774
Actas Dermosifiliogr (Engl Ed). 2019 May;110(4):279-288
pubmed: 30846164
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):345-352
pubmed: 32531099
Reprod Biol Endocrinol. 2020 Feb 17;18(1):10
pubmed: 32066450
J Am Acad Dermatol. 2012 Sep;67(3):422-8, 428.e1
pubmed: 22182915
J Am Acad Dermatol. 2010 Apr;62(4):706-8, 708.e1
pubmed: 20227585
Am J Clin Dermatol. 2017 Oct;18(5):687-695
pubmed: 28429245
J Eur Acad Dermatol Venereol. 2015 Feb;29(2):371-376
pubmed: 24909646
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):50-61
pubmed: 32460374
Acta Derm Venereol. 2018 Aug 29;98(8):757-761
pubmed: 29756157
J Eur Acad Dermatol Venereol. 2013 Apr;27(4):473-8
pubmed: 22339940
Br J Dermatol. 2017 Apr;176(4):1083-1085
pubmed: 27480611
Dermatology. 2020;236(1):37-45
pubmed: 31434072
Cells. 2021 Aug 15;10(8):
pubmed: 34440863
J Invest Dermatol. 2018 Jan;138(1):52-57
pubmed: 28942360
Exp Dermatol. 2008 May;17(5):455-6; discussion 457-72
pubmed: 18400064
J Clin Aesthet Dermatol. 2021 Aug;14(8):61-65
pubmed: 34840661
Br J Dermatol. 2017 May;176(5):1170-1178
pubmed: 28032340
Arch Sex Behav. 2007 Dec;36(6):808-20
pubmed: 17657464